The relationship between serum γ-glutamyltransferase (GGT) and diabetic nephropathy in patients with type 2 diabetes mellitus: a cross-sectional study.
Diabetic nephropathy (DN)
Predictor
Type 2 diabetes mellitus (T2DM)
γ-Glutamyltransferase (GGT)
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
03
04
2022
accepted:
04
01
2023
medline:
2
11
2023
pubmed:
12
1
2023
entrez:
11
1
2023
Statut:
ppublish
Résumé
The relationship between serum γ-glutamyltransferase (GGT) and renal dysfunction is controversial. In this study, we examined the relationship of serum GGT to diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM). A total of 577 patients with T2DM were enrolled and their basic information and laboratory data were collected and analyzed. The prevalence of DN increased with the elevated serum GGT tertiles. The level of serum GGT in the DN group was higher than in the non-DN groups. Multivariate logistic analysis showed that high GGT was independent risks for DN (OR = 1.041, 95% CIs 1.023-1.059). And the OR of log-transformed serum GGT for DN was 6.190 (95% CIs 4.248-9.021). The OR of DN across increasing tertiles of serum GGT were 1.00, 3.288 (1.851-5.840), and 5.059 (2.620-9.769) (P for trend < 0.001). Stratified receiver operating characteristic (ROC) analysis by gender showed that the area under ROC curve (AUC) value for GGT was 0.781 (0.732-0.825, P < 0.05) in male and was 0.817 (0.761-0.864, P < 0.05) in female. Compared with female, GGT in male showed lower sensitivity (52.86% vs. 82.05%) and higher specificity (90.32% vs. 55.26%). And the AUC value for GGT was greater than creatinine (Cr) and estimated glomerular filtration rate (eGFR) in male and smaller than Cr and eGFR in female, respectively. In Conclusion, there was an independently positive relationship between serum GGT levels and DN, which suggested that elevated GGT was a potential indicator for risk of DN. There were gender differences in the predictive property of GGT for DN.
Identifiants
pubmed: 36630069
doi: 10.1007/s10238-023-00991-9
pii: 10.1007/s10238-023-00991-9
doi:
Substances chimiques
gamma-Glutamyltransferase
EC 2.3.2.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3619-3630Subventions
Organisme : Wenzhou Municipal Science and Technology Bureau
ID : Y20180685
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.
doi: 10.1016/j.diabres.2018.02.023
pubmed: 29496507
Blas E, Kurup AS. Diabetes: equity and social determinants. In: Equity, social determinants and public health programmes. Geneva: World Health Organization;2010.
Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997.
doi: 10.1136/bmj.m997
pubmed: 32345662
pmcid: 7186854
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.
doi: 10.2215/CJN.11491116
pubmed: 28522654
pmcid: 5718284
Jiang W, Wang J, Shen X, et al. Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and meta-analysis of 20 cohorts. Diabetes Care. 2020;43:925–33.
doi: 10.2337/dc19-1897
pubmed: 32198286
Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia. 2008;51:1347–55.
doi: 10.1007/s00125-008-1051-7
pubmed: 18528679
Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 2010;77:57–64.
doi: 10.1038/ki.2009.399
pubmed: 19847154
pmcid: 3725722
Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, Chrousos GP, Papassotiriou I. Biomarkers of diabetic nephropathy: a 2017 update. Crit Rev Clin Lab Sci. 2017;54:326–42.
doi: 10.1080/10408363.2017.1377682
pubmed: 28956668
Currie G, McKay G, Delles C. Biomarkers in diabetic nephropathy: present and future. World J Diabetes. 2014;5:763–76.
doi: 10.4239/wjd.v5.i6.763
pubmed: 25512779
pmcid: 4265863
Abbasi F, Moosaie F, Khaloo P, Dehghani Firouzabadi F, Fatemi Abhari SM, Atainia B, Ardeshir M, Nakhjavani M, Esteghamati A. Neutrophil gelatinase-associated lipocalin and retinol-binding protein-4 as biomarkers for diabetic kidney disease. Kidney Blood Press Res. 2020;45:222–32.
doi: 10.1159/000505155
pubmed: 32008005
Quang TH, Nguyet MP, Thao DP, et al. Evaluation of urinary neutrophil gelatinase associated lipocalin and kidney injury molecule-1 as diagnostic markers for early nephropathy in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2020;13:2199–207.
doi: 10.2147/DMSO.S258678
pubmed: 32612375
pmcid: 7322140
Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia. 2018;61:996–1011.
doi: 10.1007/s00125-018-4567-5
pubmed: 29520581
pmcid: 6448994
Maobi WEI, Xiaoyan WU. Research progress of early diagnosis indicators for diabetic kidney. Med J Wuhan Univ. 2022. https://doi.org/10.14188/j.1671‑8852.2021.6020 .
doi: 10.14188/j.1671‑8852.2021.6020
Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clin Chim Acta. 2018;476:130–8.
doi: 10.1016/j.cca.2017.11.026
pubmed: 29175647
Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38:263–355.
doi: 10.1080/20014091084227
pubmed: 11563810
Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.
doi: 10.1371/journal.pmed.1001680
pubmed: 25050550
pmcid: 4106719
Kunutsor SK, Laukkanen JA. Gamma-glutamyl transferase and risk of chronic kidney disease: a prospective cohort study. Clin Chim Acta. 2017;473:39–44.
doi: 10.1016/j.cca.2017.08.014
pubmed: 28811239
Ochiai H, Shirasawa T, Yoshimoto T, et al. Elevated alanine aminotransferase and low aspartate aminotransferase/alanine aminotransferase ratio are associated with chronic kidney disease among middle-aged women: a cross-sectional study. BMC Nephrol. 2020;21:471.
doi: 10.1186/s12882-020-02144-6
pubmed: 33172399
pmcid: 7653768
Shen ZW, Xing J, Wang QL, et al. Association between serum gamma-glutamyl transferase and chronic kidney disease in urban Han Chinese: a prospective cohort study. Int Urol Nephrol. 2017;49:303–12.
doi: 10.1007/s11255-016-1429-2
pubmed: 27704320
Xu Q, Li X, Gao B, et al. Comparative performance of four equations estimating glomerular filtration rate in adult Chinese diabetics. J Endocrinol Investig. 2013;36:293–7.
De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–9.
doi: 10.1001/jama.2011.861
pubmed: 21693741
pmcid: 3731378
World Health Organization. Global status report on noncommunicable diseases. Geneva: World Health Organization; 2014.
Neuman MG, Malnick S, Chertin L. Gamma glutamyl transferase—an underestimated marker for cardiovascular disease and the metabolic syndrome. J Pharm Pharm Sci. 2020;23:65–74.
doi: 10.18433/jpps30923
pubmed: 32310756
Ma Q, Liao X, Shao C, Lin Y, Wu T, Sun Y, Feng ST, Ye J, Zhong B. Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease. BMC Gastroenterol. 2021;21:215.
doi: 10.1186/s12876-021-01790-w
pubmed: 33971815
pmcid: 8112063
Mohapatra E, Priya R, Nanda R, Patel S. Serum GGT and serum ferritin as early markers for metabolic syndrome. J Family Med Prim Care. 2020;9:3458–63.
doi: 10.4103/jfmpc.jfmpc_570_20
pubmed: 33102313
pmcid: 7567201
Al-Lamki RS, Mayadas TN. TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int. 2015;87:281–96.
doi: 10.1038/ki.2014.285
pubmed: 25140911
Pavkov ME, Weil EJ, Fufaa GD, et al. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int. 2016;89:226–34.
doi: 10.1038/ki.2015.278
pubmed: 26398493
pmcid: 4805514
Wang J, Li J, Ren Y, et al. Association between alanine aminotransferase/aspartate aminotransferase ratio (AST/ALT Ratio) and coronary artery injury in children with Kawasaki disease. Cardiol Res Pract. 2020. https://doi.org/10.1155/2020/8743548 .
doi: 10.1155/2020/8743548
pubmed: 33376603
pmcid: 7744244
Xu J, Shi X, Pan Y. The association of aspartate aminotransferase/alanine aminotransferase ratio with diabetic nephropathy in patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2021;14:3831–7.
doi: 10.2147/DMSO.S330741
pubmed: 34522109
pmcid: 8434854
Cain LR, Ducatman AM, Shankar A. The relationship between gamma-glutamyl transferase levels and chronic kidney disease among Appalachian adults. W V Med J. 2012;108:8–13.
pubmed: 25134186
Marchesini SA, Barantani EG. Aminotransferase and gamma-glutamyl transpeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Investig. 2005;28:333–9.
doi: 10.1007/BF03347199
Penno G, Solini A, Orsi E, et al. G cardiovascular events study. Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMC Med. 2021;19:66.
doi: 10.1186/s12916-021-01936-3
pubmed: 33715620
pmcid: 7962330
Thamer C, Tschritter O, Haap M, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res. 2005;37:246–51.
doi: 10.1055/s-2005-861411
pubmed: 15952086
Lippi G, Targher G, Montagnana M, Salvagno GL, Guidi GC. Relationship between gamma-glutamyltransferase, lipids and lipoprotein (a) in the general population. Clin Chim Acta. 2007;384:163–6.
doi: 10.1016/j.cca.2007.06.005
pubmed: 17601521
Zoppini G, Targher G, Trombetta M, Lippi G, Muggeo M. Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. Obesity (Silver Spring). 2009;17:370–4.
doi: 10.1038/oby.2008.544
pubmed: 19057528
Lin YL, Chang IC, Liou HH, et al. Serum indices based on creatinine and cystatin C predict mortality in patients with non-dialysis chronic kidney disease. Sci Rep. 2021;11:16863.
doi: 10.1038/s41598-021-96447-9
pubmed: 34413438
pmcid: 8377030
Krolewski AS, Warram JH, Forsblom C, et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Car. 2012;35:2311–6.
doi: 10.2337/dc11-2220